438
report
Kidney Failure - A Giving Smarter Guide
This Giving Smarter Guide is the culmination of a year-long effort to identify strategic philanthro
pic opportunities that can move the needle on unmet needs specific to kidney failure research and treatment. Kidney failure is an irreversible diseas
+ Read More
report
Hedging Pipeline Risk in Pharma: FDA Swaps and Annuities
The cost of capital to conduct medical R&D is high because investors must be compensated with s
ignificant returns to offset the risky and long drug-development process.
+ Read More
report
Alzheimer's Disease: A Giving Smarter Guide to Accelerate Development of New Therapies
The need is staggering. Alzheimer's disease is the sixth leading cause of death in the United State
s and currently, more than 5.5 million Americans are living with this disease for which there is yet no cure yet.
+ Read More
report
Funding Scientific Research - A Giving Smarter Guide
Making an Impact. Strategic philanthropic investments in medical research require a careful conside
ration of the philanthropist’s priorities and an understanding of the current state of research to amplify the impact of their giving.
+ Read More
report
Models for Biomedical Innovation and Commercialization
This report relates to a Financial Innovations Lab held in Jerusalem in 2015 that led to new work a
nd major collaborative projects between the Milken Innovation Center and universities in the U.S..
+ Read More
report
Financing the Control of Tuberculosis
As of 2015, roughly one third of the world’s population, mostly in poorer countries, carried tuberc
ulosis bacteria in their system. Given the characteristics of airborne diseases like tuberculosis, coordination among national and international age
+ Read More
report
Targeting Tau — Our Hope to Solving the Dementia Crisis
In our systems-based review of the biomedical landscape supporting research of a cellular protein c
alled tau—a common culprit in a number of neurodegenerative diseases—we make the case that focused strategic investment in tau research and the , At present, no disease-modifying therapies for the pure tauopathies exist. Researchers are working to develop effective therapeutic agents, which include approaches such as decreasing the amount of tau within the brain., Symptomatic Interventions
At present, no disease-modifying therapies for the pure tauopathies exist.
+ Read More
report
Advancing Models of Patient Engagement: Patient Organizations as Research and Data Partners
FasterCures, alongside other patient-focused advocacy organizations, has long worked with stakehold
ers such as product developers and regulators to define and implement the “how to” of patient
+ Read More
report
Misophonia - A Giving Smarter Guide
report
Financing Lung Cancer Screening in China
Lung cancer, one of the most preventable diseases, surpasses all other cancer deaths worldwide.
report
Exploring the Impact of the 21st Century Cures Act
FasterCures, a Center of the Milken Institute, and Society of Women’s Health Research (SWHR) advoca
ted for the 21st Century Cures Act, which resulted in positive changes for women’s health research.
+ Read More
report
Cornerstones of Collaboration: Foundation-Led Partnerships to Accelerate R&D
Multi-stakeholder collaboration isn’t just the participation trophy of biomedical research and deve
lopment (R&D), a nice way to make sure everyone feels included.
+ Read More